H. Lundbeck A/S said that its experimental treatment for Alzheimer’s disease, Lu AE58054, met its primary endpoint in a Phase 2 proof-of-concept study of 278 patients with moderate disease already being treated with donepezil. Full data will be disclosed at upcoming medical meetings.
